<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Iran Med</journal-id><journal-id journal-id-type="iso-abbrev">Arch Iran Med</journal-id><journal-id journal-id-type="publisher-id">Arch Iran Med</journal-id><journal-id journal-id-type="publisher-id">AIM</journal-id><journal-title-group><journal-title>Archives of Iranian Medicine</journal-title></journal-title-group><issn pub-type="ppub">1029-2977</issn><issn pub-type="epub">1735-3947</issn><issn-l>1029-2977</issn-l><publisher><publisher-name>Academy of Medical Sciences of I.R. Iran</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891453</article-id><article-id pub-id-type="pmc">PMC11786210</article-id><article-id pub-id-type="doi">10.34172/aim.31070</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Incidence and Risk Factors of Retinopathy of Prematurity in Southeastern Iran: A Retrospective Cohort Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1377-4171</contrib-id><name><surname>Maleki</surname><given-names>Alireza</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sargazi</surname><given-names>Meisam</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9139-4601</contrib-id><name><surname>Yousefian</surname><given-names>Ali</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Sarhadi</surname><given-names>Saeedeh</given-names></name><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="A03" ref-type="aff">
<sup>3</sup>
</xref><xref rid="A04" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mollaei</surname><given-names>Maryam</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7236-9745</contrib-id><name><surname>Mohammadi</surname><given-names>Seyed Omid</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A05" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="A01">
<sup>1</sup>Alzahra Eye Hospital Research Center, Zahedan University of Medical Sciences, Zahedan, Iran</aff><aff id="A02">
<sup>2</sup>Department of Ophthalmology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran</aff><aff id="A03">
<sup>3</sup>Department of Community Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran</aff><aff id="A04">
<sup>4</sup>Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran</aff><aff id="A05">
<sup>5</sup>Anne Burnett Marion School of Medicine, Texas Christian University, Fort Worth, TX, USA</aff><author-notes><corresp id="COR1">
<label>*</label><bold>Corresponding Author:</bold> Ali Yousefian, Email: <email>Ali.yousefian44@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>01</day><month>12</month><year>2024</year></pub-date><volume>27</volume><issue>12</issue><fpage>660</fpage><lpage>666</lpage><history><date date-type="received"><day>17</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>03</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Author(s).</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="https://journalaim.com">https://journalaim.com</self-uri><abstract><sec id="sa1"><title>Background:</title><p> Retinopathy of prematurity (ROP) is a significant cause of preventable premature infant vision loss. Many studies have reported different risk factors depending on the region. In this study, we evaluated the incidence of ROP and associated risk factors in a referral eye hospital in southeastern Iran.</p></sec><sec id="sa2"><title>Methods:</title><p> This was a retrospective cohort study of preterm infants with birth weight (BW)&#x02264;2000 g or gestational age (GA)&#x02264;34 weeks and infants with GA between 34-37 weeks or GA&#x0003c;37 weeks and BW&#x0003e;2000 g referred by their pediatricians to our center from March 2022 until March 2023. </p></sec><sec id="sa3"><title>Results:</title><p> Totally, 920 infants met the inclusion criteria for the study. The incidence of ROP and ROP requiring treatment was 20.2% and 3.58% respectively. Results of logistic regression analysis showed higher GA and BW as protective factors against ROP occurrence. History of blood transfusion and phototherapy increased ROP development. </p></sec><sec id="sa4"><title>Conclusion:</title><p> Lower GA, lower BW, history of blood transfusion, and phototherapy were associated with ROP development. Phototherapy decreased the need for treatment among ROP patients.</p></sec></abstract><kwd-group><kwd>Bevacizumab</kwd><kwd>Phototherapy</kwd><kwd>Retinal neovascularization</kwd><kwd>Retinopathy of prematurity</kwd><kwd>Risk factors</kwd></kwd-group></article-meta><notes><p>
<bold>Cite this article as:</bold> Maleki A, Sargazi M, Yousefian A, Sarhadi S, Mollaei M, Mohammadi SO. Incidence and risk factors of retinopathy of prematurity in southeastern Iran: a retrospective cohort study. Arch Iran Med. 2024;27(12):660-666. doi: 10.34172/aim.31070</p></notes></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p> Retinopathy of prematurity (ROP) is a significant cause of preventable premature infant vision loss. The incidence of this disease is increasing in middle-income countries due to advances in prenatal and neonatal care.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> When infants are born prematurely, the oxygen levels are increased in the extra-uterine milieu compared to <italic toggle="yes">in utero</italic>. This relative increase leads to constriction of growing vessels. Subsequently, vascular obliteration ensues and retinal ischemia causes vessel endothelial growth factor upregulation. This leads to aberrant neovascularization and retinal detachment.<sup><xref rid="R3" ref-type="bibr">3</xref>-<xref rid="R6" ref-type="bibr">6</xref></sup> Many studies have reported different risk factors depending on the region. Lower gestational age (GA) and lower birth weight (BW) are the two major risk factors for ROP development. Other risk factors associated with this condition include oxygen supplementation, multiple pregnancy, sepsis, history of blood transfusion, and intraventricular hemorrhage (IVH).<sup><xref rid="R7" ref-type="bibr">7</xref>-<xref rid="R11" ref-type="bibr">11</xref></sup> Lower BW, lower GA, pulmonary disease, and number of blood transfusions were associated with ROP severity.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup> Laser photocoagulation is the main treatment for ROP due to its safety and predictable outcomes. Intravitreal anti-vascular endothelial growth factors injection is another treatment option for the disease and promising results have been reported.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref></sup> There is no information available about the characteristics of ROP in Sistan and Baluchestan in southeastern Iran. In this study, we evaluated the incidence of ROP and its associated risk factors and provided a summary report of treatment results in a referral eye hospital.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and Methods</title><p> This was a retrospective cohort study on 920 preterm infants referred to a referral eye hospital from March 2022 until March 2023.We includedall infants with BW&#x02005;&#x02264;&#x02005;2000 g or GA&#x02005;&#x02264;&#x02005;34 weeks and infants with GA between 34-37 weeks or GA&#x02005;&#x0003c;&#x02005;37 weeks and BW&#x02005;&#x0003e;&#x02005;2000 g referred by their pediatricians. Patients who did not complete follow-up examinations and had incomplete medical and informational records were excluded.</p><p> The following data were collected and recorded: gender, BW, GA, number of pregnancies, oxygen therapy with continuous positive airway pressure (CPAP) or mechanical ventilation (number of days), history of blood transfusions, occurrence of IVH, occurrence of sepsis, phototherapy, mother&#x02019;s age, type of delivery (cesarean section versus vaginal delivery), history of hypertension during pregnancy, history of pre-eclampsia, eclampsia, and hemolysis elevated liver enzyme levels and low platelet levels (HELLP) syndrome.</p><p> The first examination was done between 4 and 6 weeks of chronological age or within the 31 and 33 weeks of postmenstrual age, whichever was later. Two experienced retina subspecialists examined infants after the instillation of tropicamide 0.5% for pupillary dilation. After topical anesthesia, fundoscopy was performed using an indirect ophthalmoscope and a &#x000b1; 20 D or &#x000b1; 30 D lens, an infant eyelid speculum, and a pediatric scleral depressor. The zones and stages of ROP were recorded based on the International Classification of Retinopathy of Prematurity, Third edition.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> The follow-up examination was done according to disease severity and continued until full retina vascularization.</p><p> In our center, treatment is performed for patients categorized as type 1 ROP, aggressive ROP, and patients with stage 4 or stage 5 ROP.<sup><xref rid="R16" ref-type="bibr">16</xref>-<xref rid="R18" ref-type="bibr">18</xref></sup> We treated ROP patients with type 1 ROP and aggressive ROP with intravitreal injection of bevacizumab 0.625 mg/0.025 mL. These patients were then re-examined on days 3 and 7 after injection and if the ROP stage, zone, and plus disease were improving, then we followed them every 1-2 weeks until the absence of neovascularization and improvement of plus disease. Then, we extended follow-up to every 3-4 weeks until 65 weeks. At this point, if retinal vascularization reached a border of less than 0.5 disc diameter away from the ora serrata in all quadrants, patients were considered to have &#x0201c;full retinal vascularization&#x0201d;, and no more follow-ups were scheduled.</p><p> Retreatment with laser was done when there was sustained neovascularization and plus disease after initial therapy with intravitreal injection of bevacizumab, or when new extra-retinal neovascularization or development of plus disease occurred after the initial response to treatment as mentioned above. We treated patients when full retinal vascularization was not achieved at 65 weeks, with laser photocoagulation.</p><sec sec-type="subsection" id="s2-1"><title> Statistical Analysis</title><p> Sample size was calculated based on the previous ROP incidence rate of 40 % (19), type 1 error of 0.05, and a margin of error of 3.2%. Using the sample size formula for population proportion, 900 eligible infants were estimated. Finally, during the period of study, 920 participants were enrolled.</p><p> Normally distributed quantitative data were described using mean and standard deviation (SD). The median and interquartile range (IQR) values represented asymmetrically distributed variables. The Kolmogorov-Smirnov test investigated the state of the normal distribution of quantitative variables. ROP risk factors were compared using the Mann-Whitney U test, chi-square, and Fisher&#x02019;s exact tests. Additionally, a comparative analysis of risk factors was performed for the data gathered from ROP patients. The Mann-Whitney U test, chi-square, and Fisher&#x02019;s exact tests were used for these comparisons. We used Fisher&#x02019;s exact tests when the chi-square requirement was not met in 2*2 tables. The expected frequencies for each cell should be at least 1, and for the majority (80%) of the cells, the expected frequencies should be at least 5. To show the strength of the relationship between the variables, the effect size was calculated. The effect size was expressed by z/&#x0221a;N for the Mann-Whitney U test. Effect size, r, was interpreted as r&#x02005;&#x02264;&#x02005;0.3 representing a small effect, 0.3&#x02005;&#x0003c;&#x02005;r&#x02005;&#x0003c;&#x02005;0.5, representing a medium effect, and 0.5&#x02005;&#x02264;&#x02005;r representing a large effect. Also, the odds ratio and confidence interval of 95% were used to express the intensity of the relationship regarding chi-square and Fisher exact tests. An odds ratio greater than one meant increased odds of occurrence of ROP or treated ROP, and on the other hand, an odds ratio less than one was interpreted as lower odds of ROP or treated ROP compared to their non-occurrence. Finally, logistic regression analysis with the &#x0201c;Enter&#x0201d; method was used to determine the variables predicting the occurrence of ROP and ROP requiring treatment. Variables that were statistically significant in the univariate analysis were included in the regression analysis. In all comparison groups, the threshold of significance was 0.05. IBM SPSS Statistics for Windows version 27.0 (IBM Corp. 2013. Armonk, NY: IBM Corp) was used to perform the analyses.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p> A total of 1143 newborn babies were referred to our hospital and screened for ROP. Of these, 920 infants met the inclusion criteria for the study. A total of 172 infants did not complete follow-up visits and 51 infants had incomplete medical records. Of 920 infants who met the inclusion criteria, 50.3% were male [n: 463]. The mean GA was 32.71&#x02005;&#x000b1;&#x02005;2.11 weeks. Mean BW was 1809.45&#x02005;&#x000b1;&#x02005;762.41 g.</p><p> Of all screened infants, 561 infants received oxygen by CPAP, 56 infants were under mechanical ventilation, 51 infants received red blood cell transfusion, five infants had a history of IVH, and 25 infants developed sepsis. Also, 301 infants were the result of multiple pregnancy.</p><p> The evaluation of risk factors and their relationship with ROP development and ROP needing treatment occurrence is shown in <xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="T2" ref-type="table">Table 2</xref>, respectively.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><title>Comparison of Risk Factors of Retinopathy of Prematurity (ROP) Between ROP and Without ROP Groups.
</title></caption><table frame="hsides" rules="none"><tbody><tr><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Variable</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Total (N=920)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>ROP (n=186)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Without ROP (n=734)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P </bold>
</italic>
<bold>Value</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Effect Size</bold>
</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1">Gestational Age (wk), Median (IQR) </td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">33.0 (32,34)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">30.0 (29,32)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">33.0 (32,34)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>a</sup></td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">0.48<sup>b</sup></td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Birth weight (g), Median (IQR) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1800 (1500,2000)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1425.0 (1195,1720)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1900.0 (1628,2100)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>a</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.41<sup>b</sup></td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Gender, Male (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">463 (50.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">95 (51.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">368 (50.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.81<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.96 (0.69-1.32)<sup>d</sup></td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Multiple births</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">301 (32.7%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">57 (30.6%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">244 (33.2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.5<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.88 (0.62-1.25)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">CPAP, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">561 (61%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">156 (83.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">405 (55.2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4.22 (2.78-6.40)<sup>d</sup></td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Days on CPAP</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.18 (1.8)<break/>1.00 (2.00)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.83 (2.70)<break/>1.00 (1.44)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.02 (1.44)<break/>1.00(1.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>a</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.15</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Mechanical ventilation, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">56 (6.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">23 (12.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">33 (4.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.99 (1.71-5.24)<sup>d</sup></td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Days on mechanical ventilation</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.10 (0.54)<break/>0.00 (0.00)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.14 (0.67)<break/>0.00 (0.00)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.09 (0.5)<break/>0.00 (0.00)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.053 <sup>a</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.06</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Blood transfusion, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">51 (5.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">36 (19.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11.5 (6.14-21.54)<sup>d</sup></td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Intraventricular hemorrhage, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (0.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (1.6%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (0.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.059<sup>e</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6.0 (0.99-36.1)<sup>d</sup></td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Sepsis, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">25 (2.7%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (7.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (1.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5.34 (2.38-11.9)<sup>d</sup></td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Phototherapy, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">684 (74.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">155 (83.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">529 (72.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.002<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.93 (1.27-2.94)<sup>d</sup></td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Type of delivery, C/S, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">606 (65.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">104 (55.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">502 (68.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.001<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.7 (1.22-2.37)<sup>d</sup></td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">
<italic toggle="yes">In vitro</italic> fertilization (IVF), N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">73 (7.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (7.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">59 (8%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.81<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.93 (0.50-1.70)<sup>d</sup></td></tr><tr style="background-color:#e3e8e1"><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">Cause of premature <break/>Birth, N (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Onset of labor pains</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">334 (36.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">77 (41.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">257 (35%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.09<sup>c</sup></td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Rupture of the amniotic sac</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">373 (40.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">77 (41.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">296 (40.3%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hypertension</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">140 (15.2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">24 (12.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">116 (15.8%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Other (preeclampsia, eclampsia, doctor&#x02019;s diagnosis, HELLP syndrome)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">73 (7.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (4.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">65 (8.9%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1">Age of mother (year), Median (IQR) </td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">29.0 (22,33)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">25.0 (21,32)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">29.0 (23,34)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>a</sup></td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.10<sup>b</sup></td></tr></tbody></table><table-wrap-foot><fn><p> SD, standard deviation; IQR, interquartile range;CPAP, Continuous positive airway pressure;C/S, cesarean section.</p><p>
<sup>a</sup>Mann-Whitney U test.</p><p>
<sup>b</sup>Effect size measure for Mann-Whitney U analysiswith r&#x02005;=&#x02005;z/&#x0221a;N.</p><p>
<sup>c</sup>Chi-square test.</p><p>
<sup>d</sup>Odds ratio (95% confidence interval).</p><p>
<sup>e</sup>Fisher&#x02019;s exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><title>Comparison of Risk Factors of Retinopathy of Prematurity (ROP) Between ROP with and without Treatment Groups
</title></caption><table frame="hsides" rules="none"><tbody><tr><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Variable</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Total, N=186</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Treatment</bold>
<break/>
<bold>Needed (n=33)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Without Treatment (n=153)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P </bold>
</italic>
<bold>Value</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Effect Size</bold>
</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Gestational Age (wk), Median (IQR) </td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">30.0 (29,32)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">29.0 (27,30)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">31.0 (29,32)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>a</sup></td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">0.35<sup>b</sup></td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Birth weight (g), Median (IQR) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1425.0 (1195,1720)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1115.0 (1000,1315)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1500.0 (1255,1767.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>a</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.35<sup>b</sup></td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Gender, Male, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">95 (51.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (42.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">81 (52.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.27<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.52 (0.71-3.26)<sup>d</sup></td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Multiple births</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">57 (30.6%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (42.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">43 (28.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.106<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.88 (0.86-4.09) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">CPAP, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">156 (83.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27 (81.8%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">129 (84.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.72<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.83 (0.31-2.24)<sup>d</sup></td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Days on CPAP</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.8 (2.7)<break/>1 (1.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.96 (2.88)<break/>1.00 (1.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.81 (2.67)<break/>1.00 (2.00)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.45<sup>a</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.05</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Mechanical ventilation, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">23 (12.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (24.2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (9.8%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.02<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.94 (1.12-7.67)<sup>d</sup></td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Days on mechanical ventilation</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.14 (0.67)<break/>0.00 (0.00)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.12 (0.33)<break/>0.00 (0.00)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.15 (0.73)<break/>0.00 (0.00)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.55<sup>a</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.04</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Blood transfusion, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">36 (19.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (42.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (14.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4.38 (1.92-10.1)<sup>d</sup></td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Intraventricular hemorrhage, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (1.6%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (1.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.44<sup>e</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.35 (0.20-26.8)<sup>d</sup></td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Sepsis, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (7.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (12.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (6.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.27<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.97 (0.57-6.72)<sup>d</sup></td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Phototherapy, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">155 (83.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (66.7%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">133 (86.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.005<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.30 (0.12-0.71)<sup>d</sup></td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Type of delivery, C/S, N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">104 (55.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">21 (63.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">83 (54.2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.32<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.67 (0.31-1.47)<sup>d</sup></td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
<italic toggle="yes">In vitro</italic> fertilization (IVF), N (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (7.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (12.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (6.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.27<sup>c</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.97 (0.57-6.72)<sup>d</sup></td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Cause of premature birth, N (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Onset of labor pains</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">77 (41.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (48.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">61 (39.9%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Rupture of the amniotic sac</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">77 (41.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (30.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">67 (43.8%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.54<sup>c</sup></td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hypertension</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">24 (12.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (15.2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">19 (12.4%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Other (preeclampsia, eclampsia, doctor&#x02019;s diagnosis, HELLP syndrome)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (4.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (6.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (3.9%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">Age of mother (year), Median (IQR) </td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">25.0 (21,32)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">25.0 (21,32)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">24.0 (20,32)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.70<sup>a</sup></td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.02<sup>b</sup></td></tr></tbody></table><table-wrap-foot><fn><p> SD, standard deviation; IQR, interquartile range;CPAP, Continuous positive airway pressure;C/S, cesarean section.</p><p>
<sup>a</sup>Mann Whitney U test.</p><p>
<sup>b</sup>effect size measure for Mann-Whitney U analysiswith r&#x02005;=&#x02005;z/&#x0221a;N.</p><p>
<sup>c</sup>chi-square test.</p><p>
<sup>d</sup>odds ratio (95% confidence interval).</p><p>
<sup>e</sup>Fisher&#x02019;s exact test.</p></fn></table-wrap-foot></table-wrap><p> Univariate analysis showed statistically significant relationships between the occurrence of ROP and GA, BW, being under CPAP, the number of days under CPAP, being under mechanical ventilation, history of blood transfusion, history of sepsis, phototherapy, type of delivery (cesarean section), and lower maternal age (<xref rid="T1" ref-type="table">Table 1</xref>). The results of multivariate logistic regression analysis showed higher GA and BW as protective factors against ROP occurrence. History of blood transfusion and phototherapy increased ROP development. Additionally, phototherapy decreased ROP requiring treatment occurrence as shown in the logistic regression analysis in <xref rid="T3" ref-type="table">Table 3</xref>.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><title>Risk Factors for Retinopathy of Prematurity (ROP) and ROP Requiring Treatment Occurrence: Results of Logistic Regression Analysis
</title></caption><table frame="hsides" rules="none"><tbody><tr><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Variables</bold></td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Significance</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Odds Ratio</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>95%CI</bold></td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Gestational Age</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">0.589</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">0.512-0.678</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Birth weight</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.998</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.998-0.999</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Blood transfusion</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6.357</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.53-15.97</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Phototherapy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.006</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.172</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.24-3.78</td></tr><tr style="background-color:#e3e8e1"><td colspan="4" style="text-align:left;vertical-align:middle;" rowspan="1">Risk factors for ROP requiring treatment occurrence: results of logistic regression analysis</td></tr><tr><td style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">Phototherapy</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.035</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.349</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.131-0.927</td></tr></tbody></table><table-wrap-foot><fn><p> CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><p> A total of 186 infants had ROP and the incidence of ROP in our study was 20.2%. Twenty patients out of 33 ROP patients who needed treatment were in the&#x02005;&#x02264;&#x02005;30 weeks GA group. There were 15 ROP patients in the&#x02005;&#x02264;&#x02005;1000-g BW group and seven of them required treatment, although most ROP patients who needed treatment had 1000&#x02005;&#x0003c;&#x02005;BW&#x02005;&#x02264;&#x02005;1500 g (<xref rid="T4" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><title>Incidence of ROP and ROP Requiring Treatment in Different Gestational Age and Birth Weight Groups.
</title></caption><table frame="hsides" rules="none"><tbody><tr><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Total</bold>
<break/>
<bold> N=920</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>ROP</bold>
<break/>
<bold>(n=186)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Without ROP</bold>
<break/>
<bold>(n=734)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>ROP With Treatment </bold>
<break/>
<bold>(n=33)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>ROP Without Treatment (n=153)</bold>
</td></tr><tr style="background-color:#e3e8e1"><td rowspan="4" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">Gestational Age category (wk),<break/>No. (%)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;34 </td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">172 (18.7%)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">4 (2.2%)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">168 (22.9%)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">0 (0%)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">4 (2.6%)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">32&#x02005;&#x0003c;&#x02005;-&#x02005;&#x02264;&#x02005;34</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">526 (57.2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">56 (30.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">470 (64%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (6.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">54 (35.3%)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30&#x02005;&#x0003c;&#x02005;-&#x02005;&#x02264;&#x02005;32</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">151 (16.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">65 (34.9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">86 (11.7%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (33.3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">54 (35.3%)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x02264;&#x02005;30</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">71 (7.7%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">61 (32.8%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (1.4%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">20 (60.6%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">41 (26.8%)</td></tr><tr><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">Birth weight category<break/>(g), No. (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;2000</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">222 (24.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (4.8%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">213 (29%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (5.9%)</td></tr><tr><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1500&#x02005;&#x0003c;&#x02005;-&#x02005;&#x02264;&#x02005;2000</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">499 (54.2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">77 (41.1%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">422 (57.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (18.2%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">71 (46.4%)</td></tr><tr><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1000&#x02005;&#x0003c;&#x02005;-&#x02005;&#x02264;&#x02005;1500</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">179 (19.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">85 (45.7%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">94 (12.8%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">20 (60.6%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">65 (42.5%)</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">&#x02005;&#x02264;&#x02005;1000</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">20 (2.2%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">15 (8.1%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">5 (0.7%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">7 (21.2%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">8 (5.2%)</td></tr></tbody></table></table-wrap><p> Of the 33 patients treated in our center, 22 patients had type 1 ROP and 6 patients had aggressive ROP. We treated these 28 patients primarily with intravitreal bevacizumab (IVB) injection. Nine patients out of 28 patients needed laser retreatment. Five patients out of 33 patients had type 2 ROP and full retinal vascularization was not achieved at 65 weeks follow-up, so we treated them primarily with laser photocoagulation. There were no patients with stage 4 or stage 5 ROP during the period of our study.</p></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p> The incidence of ROP varies between different studies. Even in studies from various parts of Iran as shown in <xref rid="T5" ref-type="table">Table 5</xref>, screening programs, population heterogeneity, level of perinatal care, and NICU (neonatal intensive care unit) care may influence the statistical differences.<sup><xref rid="R13" ref-type="bibr">13</xref></sup></p><table-wrap position="float" id="T5"><label>Table 5</label><caption><title>Incidence of ROP Occurrence in Different Studies
</title></caption><table frame="hsides" rules="none"><tbody><tr><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Author</bold>
<break/>
<bold>Year of Publication</bold>
<break/>
<bold>Country </bold>
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Study Design</bold>
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Inclusion Criteria</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Number of Patients</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>ROP Incidence (%)</bold>
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold> Risk Factors</bold>
</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Hu et al<sup><xref rid="R19" ref-type="bibr">19</xref></sup><break/>2023<break/>China</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">retrospective case&#x02013;control study</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">BW&#x02005;&#x0003c;&#x02005;1500 g</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">611</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">40.1%</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Lower GA, twin birth, moderate to severe bronchopulmonary disorder</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Bas et al<sup><xref rid="R7" ref-type="bibr">7</xref></sup><break/>2018<break/>Turkey</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">prospective cohort study </td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">BW&#x02005;&#x02264;&#x02005;1500 g or GA&#x02005;&#x02264;&#x02005;32 weeks and those with a BW&#x02005;&#x0003e;&#x02005;1500 g or GA&#x02005;&#x0003e;&#x02005;32 weeks with an unstable clinical course</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6115</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27.0%</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">lower BW, smaller GA, total days on oxygen, late-onset sepsis, frequency of red blood cell transfusions and relative weight gain</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Deb et al<sup><xref rid="R20" ref-type="bibr">20</xref></sup><break/>2023<break/>India </td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">prospective cohort study </td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">GA&#x02005;&#x0003c;&#x02005;35 weeks and BW&#x02005;&#x0003c;&#x02005;2500 gs</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">574</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28.7%</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">lower BW, acyanotic heart disease, sepsis</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">&#x000c7;&#x000f6;mez et al<sup><xref rid="R21" ref-type="bibr">21</xref></sup><break/>2022<break/>Turkey</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Retrospective<break/>Cohort study</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">GA&#x02005;&#x0003e;&#x02005;31 &#x000b1; 6 weeks to 36 &#x000b1; 6 weeks</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4156</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22%</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">duration of hospital stay, BW and GA</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Freitas et al<sup><xref rid="R13" ref-type="bibr">13</xref></sup><break/>2018<break/>Brazil</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">retrospective cohort study</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">GA l&#x02005;&#x0003c;&#x02005;32 weeks or BW&#x02005;&#x0003c;&#x02005;1500 g; or neonates born with 32-37 weeks' gestation or BW above 1500 g and any of the following associated: multiple gestation, respiratory distress syndrome, sepsis, blood transfusions or IVH</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">602 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">33.9%</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">extremely low BW, pulmonary diseases, IVH, and low GA</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Al-Qahtani et al<sup><xref rid="R10" ref-type="bibr">10</xref></sup><break/>2020<break/>Saudi Arabia</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">retrospective cohort study</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">BW&#x02005;&#x0003c;&#x02005;1501 g or GA&#x02005;&#x0003c;&#x02005;32 weeks</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">581</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">38.6%</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">BW, GA, Postnatal steroid, O2 therapy, IVH, RBC transfusion</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Dani et al<sup><xref rid="R22" ref-type="bibr">22</xref></sup><break/>2021<break/>Italy</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">cohort </td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">GA between 23 and 30 weeks</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">178</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">38%</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">IVH, RBC transfusion</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Zarei et al<sup><xref rid="R23" ref-type="bibr">23</xref></sup><break/>2019<break/>Iran</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">retrospective cohort study</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">GA&#x02005;&#x02264;&#x02005;37 weeks</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1,990</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27.28%</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">GA, BW, and history of transfusion</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Abrishami et al<sup><xref rid="R9" ref-type="bibr">9</xref></sup><break/>2013<break/>Iran</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">cross-sectional study</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;32 gestational weeks</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">122</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 26.2%</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">GA, sex, BW, Apgar score, duration of parenteral nutrition, oxygen therapy, phototherapy, maximum PaO2 and minimum SpO2 (univariate analysis)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Alizadeh et al<sup><xref rid="R24" ref-type="bibr">24</xref></sup><break/>2015<break/>Iran</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">cross-sectional study</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">BW&#x02005;&#x02264;&#x02005;2500 g and/or GA&#x02005;&#x02264;&#x02005;36 weeks</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">310</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">20.6%</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">low GA and low BW</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">Khorshidifar et al<sup><xref rid="R25" ref-type="bibr">25</xref></sup><break/>2019<break/>Iran</td><td style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">cross-sectional study</td><td style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">BW&#x02005;&#x02264;&#x02005;2000 g or GA&#x02005;&#x0003c;&#x02005;34 weeks and all other infants at risk of ROP admitted to the NICU or referred to our ROP clinic</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">207</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">33.3%</td><td style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">BW, GA and blood transfusion</td></tr></tbody></table><table-wrap-foot><fn><p> GA, gestational age; BW, birth weight; IVH, intraventricular hemorrhage; NICU, neonatal intensive care unit; RBC, red blood cell.</p></fn></table-wrap-foot></table-wrap><p> The incidence of ROP in our study was 20.2% among infants with BW&#x02005;&#x02264;&#x02005;2000 g or GA&#x02005;&#x02264;&#x02005;34 weeks or preterm infants with GA above 34 weeks or with BW above 2000 G with unstable clinical conditions referred by neonatologists.</p><p> Totally, 185 patients with ROP had BW&#x02005;&#x02264;&#x02005;2000-G or GA&#x02005;&#x02264;&#x02005;34 weeks and only one patient did not fit in the previously mentioned inclusion criteria selected. This patient was directly referred for evaluation by a pediatrician.</p><p> By implementing other criteria such as BW&#x02005;&#x02264;&#x02005;1500 G or GA&#x02005;&#x02264;&#x02005;32 weeks, BW&#x02005;&#x02264;&#x02005;2000 G or GA&#x02005;&#x02264;&#x02005;32 weeks, BW&#x02005;&#x02264;&#x02005;1500 G or GA&#x02005;&#x02264;&#x02005;34 weeks, 27 ROP patients, 6 ROP patients, and 4 ROP patients would be missed, respectively.</p><p> The mean GA and BW of infants who developed ROP were 30.4&#x02005;&#x000b1;&#x02005;2.1 weeks and 1447.8&#x02005;&#x000b1;&#x02005;354.8 G, respectively. For ROP patients requiring treatment, the mean GA and BW were 28.84&#x02005;&#x000b1;&#x02005;1.6 weeks and 1185.6&#x02005;&#x000b1;&#x02005;294.8 G, respectively. The mean GA and BW for ROP requiring treatment in our study are within the range of GA 24-32 weeks and BW 700-1480 G previously reported by Khorshidifar et al in their study of ROP in Tehran, the capital of Iran.<sup><xref rid="R25" ref-type="bibr">25</xref></sup></p><p> Identifying risk factors for developing ROP helps set screening criteria, reduce unnecessary examinations, and may help prevent ROP occurrence or progression. Lower GA, lower BW, multiple births, red blood cell transfusions, phototherapy, IVH, supplemental oxygen therapy, sepsis occurrence, and pulmonary diseases are among the risk factors mentioned in the studies, as shown in <xref rid="T5" ref-type="table">Table 5</xref>.</p><p> Like many other studies, lower BW and lower GA were correlated with ROP development.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R23" ref-type="bibr">23</xref>-<xref rid="R25" ref-type="bibr">25</xref></sup></p><p> Lower GA and lower BW suggest infants are more immature and are at risk for developing ROP due to general immaturity.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p><p> Blood transfusion was a risk factor for ROP development in our study. A lower concentration of HbF has been associated with ROP development.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Blood transfusion replaces fetal hemoglobin (HbF) with adult hemoglobin (HbA) and may cause ROP development by increasing retinal oxygen delivery.<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup></p><p> Phototherapy increased the risk of ROP development in our study. The antioxidant effects of bilirubin can be protective against ROP.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> However, in ROP patients, it reduced the need for treatment and was the only protective factor against ROP requiring treatment occurrence in our study.</p><p> Gaton et al showed no protective role for bilirubin against ROP occurrence and no relation between ROP severity and bilirubin levels.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> However, a study by Boskabadi et al suggested that higher bilirubin levels may be protective against ROP development and may reduce ROP severity.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> It seems that the role of phototherapy as an independent factor needs further evaluation.</p><p> Laser photocoagulation of avascular retina is the most common treatment for ROP, but it reduces the patient&#x02019;s visual field significantly. In recent years, intravitreal anti-VEGF injections have been implemented. Although higher recurrence is reported in some studies, there is controversy between studies about the recurrence rate. Retinal tissue ablation, visual field reduction, and myopia occurrence are lower compared to laser photocoagulation.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R32" ref-type="bibr">32</xref>-<xref rid="R34" ref-type="bibr">34</xref></sup></p><p> In our study, the incidence of ROP requiring treatment was 3.58 %. A total of 28 patients received IVB injections as first treatment and 19 patients out of 28 patients achieved complete retinal vascularization during follow-up examinations. We followed up with the patients until 65 weeks of gestation and none of them showed recurrence after ROP regression.</p><p> Nine out of 28 patients treated with IVB injection needed laser retreatment; six of them had aggressive ROP and did not respond well to primary IVB treatment, and three patients had type 1 ROP which showed incomplete vascularization until the 65-week follow-up visit.</p><p> All patients who needed treatment in our study had GA&#x02005;&#x02264;&#x02005;34 weeks and BW&#x02005;&#x02264;&#x02005;2000 g. One limitation of our study is the retrospective design, which decreased our control on evaluations. The strength of our study is the large number of patients evaluated in our center.</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p> The incidence of ROP occurrence in our study was 20.2%. Lower GA, lower BW, history of blood transfusion, and phototherapy were associated with ROP development. The incidence of ROP requiring treatment occurrence was 3.58% and phototherapy decreased the need for treatment among ROP patients.</p></sec></body><back><fn-group><fn id="n1" fn-type="COI-statement"><p>
<bold>Competing Interests</bold>
</p><p> All authors declare that they have no conflict of interest.</p></fn><fn id="n2" fn-type="other"><p>
<bold>Ethical Approval</bold>
</p><p> The Ethics Committee of Zahedan University of Medical Sciences approved the project and the ethical principles in the Declaration of Helsinki were followed.</p></fn><fn id="n3" fn-type="financial-disclosure"><p>
<bold>Funding</bold>
</p><p> None.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ludwig</surname><given-names>CA</given-names></name>
<name><surname>Chen</surname><given-names>TA</given-names></name>
<name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name>
<name><surname>Moshfeghi</surname><given-names>AA</given-names></name>
<name><surname>Moshfeghi</surname><given-names>DM</given-names></name>
</person-group><article-title>The epidemiology of retinopathy of prematurity in the United States</article-title><source>Ophthalmic Surg Lasers Imaging Retina</source><year>2017</year><volume>48</volume><issue>7</issue><fpage>553</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.3928/23258160-20170630-06</pub-id><pub-id pub-id-type="pmid">28728176</pub-id>
</element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gilbert</surname><given-names>C</given-names></name>
</person-group><article-title>Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control</article-title><source>Early Hum Dev</source><year>2008</year><volume>84</volume><issue>2</issue><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.earlhumdev.2007.11.009</pub-id><pub-id pub-id-type="pmid">18234457</pub-id>
</element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartnett</surname><given-names>ME</given-names></name>
<name><surname>Penn</surname><given-names>JS</given-names></name>
</person-group><article-title>Mechanisms and management of retinopathy of prematurity</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><issue>26</issue><fpage>2515</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1208129</pub-id><pub-id pub-id-type="pmid">23268666</pub-id>
</element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beharry</surname><given-names>KD</given-names></name>
<name><surname>Valencia</surname><given-names>GB</given-names></name>
<name><surname>Lazzaro</surname><given-names>DR</given-names></name>
<name><surname>Aranda</surname><given-names>JV</given-names></name>
</person-group><article-title>Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity</article-title><source>Semin Perinatol</source><year>2016</year><volume>40</volume><issue>3</issue><fpage>189</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1053/j.semperi.2015.12.006</pub-id><pub-id pub-id-type="pmid">26831641</pub-id>
</element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hellstr&#x000f6;m</surname><given-names>A</given-names></name>
<name><surname>H&#x000e5;rd</surname><given-names>AL</given-names></name>
</person-group><article-title>Screening and novel therapies for retinopathy of prematurity - a review</article-title><source>Early Hum Dev</source><year>2019</year><volume>138</volume><fpage>104846</fpage><pub-id pub-id-type="doi">10.1016/j.earlhumdev.2019.104846</pub-id><pub-id pub-id-type="pmid">31474316</pub-id>
</element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>LE</given-names></name>
</person-group><article-title>Pathogenesis of retinopathy of prematurity</article-title><source>Growth Horm IGF Res</source><year>2004</year><volume>14 Suppl A</volume><fpage>S140</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.ghir.2004.03.030</pub-id><pub-id pub-id-type="pmid">15135797</pub-id>
</element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bas</surname><given-names>AY</given-names></name>
<name><surname>Demirel</surname><given-names>N</given-names></name>
<name><surname>Koc</surname><given-names>E</given-names></name>
<name><surname>Ulubas Isik</surname><given-names>D</given-names></name>
<name><surname>Hirfanoglu &#x00130;</surname><given-names>M</given-names></name>
<name><surname>Tunc</surname><given-names>T</given-names></name>
</person-group><article-title>Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units</article-title><source>Br J Ophthalmol</source><year>2018</year><volume>102</volume><issue>12</issue><fpage>1711</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2017-311789</pub-id><pub-id pub-id-type="pmid">29519879</pub-id>
</element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Xun</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>YC</given-names></name>
<name><surname>Wang</surname><given-names>B</given-names></name>
<name><surname>Geng</surname><given-names>SH</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Incidence and risk factors of retinopathy of prematurity in two neonatal intensive care units in North and South China</article-title><source>Chin Med J (Engl)</source><year>2015</year><volume>128</volume><issue>7</issue><fpage>914</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4103/0366-6999.154294</pub-id><pub-id pub-id-type="pmid">25836612</pub-id>
</element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abrishami</surname><given-names>M</given-names></name>
<name><surname>Maemori</surname><given-names>GA</given-names></name>
<name><surname>Boskabadi</surname><given-names>H</given-names></name>
<name><surname>Yaeghobi</surname><given-names>Z</given-names></name>
<name><surname>Mafi-Nejad</surname><given-names>S</given-names></name>
<name><surname>Abrishami</surname><given-names>M</given-names></name>
</person-group><article-title>Incidence and risk factors of retinopathy of prematurity in Mashhad, northeast Iran</article-title><source>Iran Red Crescent Med J</source><year>2013</year><volume>15</volume><issue>3</issue><fpage>229</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.5812/ircmj.4513</pub-id><pub-id pub-id-type="pmid">23984003</pub-id>
</element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Qahtani</surname><given-names>B</given-names></name>
<name><surname>Al-Otaibi</surname><given-names>M</given-names></name>
<name><surname>Alabdulajabbar</surname><given-names>K</given-names></name>
<name><surname>Selayem</surname><given-names>NB</given-names></name>
<name><surname>Alshehri</surname><given-names>W</given-names></name>
<name><surname>Omair</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Retinopathy of prematurity incidence and risk factors in a tertiary hospital in Riyadh, Saudi Arabia</article-title><source>Middle East Afr J Ophthalmol</source><year>2019</year><volume>26</volume><issue>4</issue><fpage>235</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4103/meajo.MEAJO_131_18</pub-id><pub-id pub-id-type="pmid">32153336</pub-id>
</element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabzehei</surname><given-names>MK</given-names></name>
<name><surname>Afjeh</surname><given-names>SA</given-names></name>
<name><surname>Dastjani Farahani</surname><given-names>A</given-names></name>
<name><surname>Shamshiri</surname><given-names>AR</given-names></name>
<name><surname>Esmaili</surname><given-names>F</given-names></name>
</person-group><article-title>Retinopathy of prematurity: incidence, risk factors, and outcome</article-title><source>Arch Iran Med</source><year>2013</year><volume>16</volume><issue>9</issue><fpage>507</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">23981152</pub-id>
</element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Englert</surname><given-names>JA</given-names></name>
<name><surname>Saunders</surname><given-names>RA</given-names></name>
<name><surname>Purohit</surname><given-names>D</given-names></name>
<name><surname>Hulsey</surname><given-names>TC</given-names></name>
<name><surname>Ebeling</surname><given-names>M</given-names></name>
</person-group><article-title>The effect of anemia on retinopathy of prematurity in extremely low birth weight infants</article-title><source>J Perinatol</source><year>2001</year><volume>21</volume><issue>1</issue><fpage>21</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/sj.jp.7200511</pub-id><pub-id pub-id-type="pmid">11268863</pub-id>
</element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freitas</surname><given-names>AM</given-names></name>
<name><surname>M&#x000f6;rschb&#x000e4;cher</surname><given-names>R</given-names></name>
<name><surname>Thorell</surname><given-names>MR</given-names></name>
<name><surname>Rhoden</surname><given-names>EL</given-names></name>
</person-group><article-title>Incidence and risk factors for retinopathy of prematurity: a retrospective cohort study</article-title><source>Int J Retina Vitreous</source><year>2018</year><volume>4</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s40942-018-0125-z</pub-id><pub-id pub-id-type="pmid">29881640</pub-id>
</element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Good</surname><given-names>WV</given-names></name>
</person-group><article-title>The early treatment for retinopathy of prematurity study: structural findings at age 2 years</article-title><source>Br J Ophthalmol</source><year>2006</year><volume>90</volume><issue>11</issue><fpage>1378</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1136/bjo.2006.098582</pub-id><pub-id pub-id-type="pmid">16914473</pub-id>
</element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frosini</surname><given-names>S</given-names></name>
<name><surname>Franco</surname><given-names>F</given-names></name>
<name><surname>Vicini</surname><given-names>G</given-names></name>
<name><surname>Nicolosi</surname><given-names>C</given-names></name>
<name><surname>Varriale</surname><given-names>G</given-names></name>
<name><surname>Dani</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review</article-title><source>J Matern Fetal Neonatal Med</source><year>2022</year><volume>35</volume><issue>17</issue><fpage>3337</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1080/14767058.2020.1818214</pub-id><pub-id pub-id-type="pmid">32933350</pub-id>
</element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiang</surname><given-names>MF</given-names></name>
<name><surname>Quinn</surname><given-names>GE</given-names></name>
<name><surname>Fielder</surname><given-names>AR</given-names></name>
<name><surname>Ostmo</surname><given-names>SR</given-names></name>
<name><surname>Paul Chan</surname><given-names>RV</given-names></name>
<name><surname>Berrocal</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>International classification of retinopathy of prematurity, third edition</article-title><source>Ophthalmology</source><year>2021</year><volume>128</volume><issue>10</issue><fpage>e51</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2021.05.031</pub-id><pub-id pub-id-type="pmid">34247850</pub-id>
</element-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="other"> Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684-94. <pub-id pub-id-type="doi">10.1001/archopht.121.12.1684</pub-id>.</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="other"> International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991-9. <pub-id pub-id-type="doi">10.1001/archopht.123.7.991</pub-id>.</mixed-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>M</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Han</surname><given-names>S</given-names></name>
<name><surname>Zhu</surname><given-names>J</given-names></name>
</person-group><article-title>Incidence and risk factors for retinopathy of prematurity in a tertiary hospital in China</article-title><source>Clin Ophthalmol</source><year>2023</year><volume>17</volume><fpage>3189</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.2147/opth.S434173</pub-id><pub-id pub-id-type="pmid">37904850</pub-id>
</element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deb</surname><given-names>D</given-names></name>
<name><surname>Annamalai</surname><given-names>R</given-names></name>
<name><surname>Muthukumar</surname><given-names>M</given-names></name>
</person-group><article-title>Incidence, risk factors, progression, and involution in retinopathy of prematurity at a tertiary care center in South India</article-title><source>Oman J Ophthalmol</source><year>2023</year><volume>16</volume><issue>3</issue><fpage>452</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.4103/ojo.ojo_239_22</pub-id><pub-id pub-id-type="pmid">38059079</pub-id>
</element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000c7;&#x000f6;mez</surname><given-names>A</given-names></name>
<name><surname>&#x000c7;elemler</surname><given-names>P</given-names></name>
<name><surname>&#x000d6;zmen</surname><given-names>MC</given-names></name>
<name><surname>Yurttutan</surname><given-names>S</given-names></name>
<name><surname>Akkececi</surname><given-names>NS</given-names></name>
<name><surname>G&#x000fc;ng&#x000f6;r</surname><given-names>K</given-names></name>
<etal/>
</person-group><article-title>Retinopathy of prematurity incidence and treatment modalities in moderate and late preterm infants: a study from two tertiary centers</article-title><source>Can J Ophthalmol</source><year>2022</year><volume>57</volume><issue>3</issue><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.jcjo.2021.03.014</pub-id><pub-id pub-id-type="pmid">33887261</pub-id>
</element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dani</surname><given-names>C</given-names></name>
<name><surname>Coviello</surname><given-names>C</given-names></name>
<name><surname>Panin</surname><given-names>F</given-names></name>
<name><surname>Frosini</surname><given-names>S</given-names></name>
<name><surname>Costa</surname><given-names>S</given-names></name>
<name><surname>Purcaro</surname><given-names>V</given-names></name>
<etal/>
</person-group><article-title>Incidence and risk factors of retinopathy of prematurity in an Italian cohort of preterm infants</article-title><source>Ital J Pediatr</source><year>2021</year><volume>47</volume><issue>1</issue><fpage>64</fpage><pub-id pub-id-type="doi">10.1186/s13052-021-01011-w</pub-id><pub-id pub-id-type="pmid">33712037</pub-id>
</element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zarei</surname><given-names>M</given-names></name>
<name><surname>Bazvand</surname><given-names>F</given-names></name>
<name><surname>Ebrahimiadib</surname><given-names>N</given-names></name>
<name><surname>Roohipoor</surname><given-names>R</given-names></name>
<name><surname>Karkhaneh</surname><given-names>R</given-names></name>
<name><surname>Farahani Dastjani</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Prevalence and risk factors of retinopathy of prematurity in Iran</article-title><source>J Ophthalmic Vis Res</source><year>2019</year><volume>14</volume><issue>3</issue><fpage>291</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.18502/jovr.v14i3.4785</pub-id><pub-id pub-id-type="pmid">31660108</pub-id>
</element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alizadeh</surname><given-names>Y</given-names></name>
<name><surname>Zarkesh</surname><given-names>M</given-names></name>
<name><surname>Soltani Moghadam</surname><given-names>R</given-names></name>
<name><surname>Esfandiarpour</surname><given-names>B</given-names></name>
<name><surname>Behboudi</surname><given-names>H</given-names></name>
<name><surname>Karambin</surname><given-names>MM</given-names></name>
<etal/>
</person-group><article-title>Incidence and risk factors for retinopathy of prematurity in north of Iran</article-title><source>J Ophthalmic Vis Res</source><year>2015</year><volume>10</volume><issue>4</issue><fpage>424</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4103/2008-322x.176907</pub-id><pub-id pub-id-type="pmid">27051487</pub-id>
</element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khorshidifar</surname><given-names>M</given-names></name>
<name><surname>Nikkhah</surname><given-names>H</given-names></name>
<name><surname>Ramezani</surname><given-names>A</given-names></name>
<name><surname>Entezari</surname><given-names>M</given-names></name>
<name><surname>Daftarian</surname><given-names>N</given-names></name>
<name><surname>Norouzi</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Incidence and risk factors of retinopathy of prematurity and utility of the national screening criteria in a tertiary center in Iran</article-title><source>Int J Ophthalmol</source><year>2019</year><volume>12</volume><issue>8</issue><fpage>1330</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.18240/ijo.2019.08.15</pub-id><pub-id pub-id-type="pmid">31456925</pub-id>
</element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fortes Filho</surname><given-names>JB</given-names></name>
<name><surname>Eckert</surname><given-names>GU</given-names></name>
<name><surname>Valiatti</surname><given-names>FB</given-names></name>
<name><surname>Dos Santos</surname><given-names>PG</given-names></name>
<name><surname>da Costa</surname><given-names>MC</given-names></name>
<name><surname>Procianoy</surname><given-names>RS</given-names></name>
</person-group><article-title>The influence of gestational age on the dynamic behavior of other risk factors associated with retinopathy of prematurity (ROP)</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2010</year><volume>248</volume><issue>6</issue><fpage>893</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1007/s00417-009-1248-6</pub-id><pub-id pub-id-type="pmid">20016911</pub-id>
</element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>N</given-names></name>
<name><surname>Dubey</surname><given-names>A</given-names></name>
<name><surname>Kumar</surname><given-names>K</given-names></name>
<name><surname>Shrivastava</surname><given-names>J</given-names></name>
</person-group><article-title>Role of fetal hemoglobin in the development and progression of retinopathy of prematurity in preterm infants</article-title><source>Indian J Ophthalmol</source><year>2023</year><volume>71</volume><issue>11</issue><fpage>3478</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.4103/ijo.Ijo_274_23</pub-id><pub-id pub-id-type="pmid">37870010</pub-id>
</element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Villeneuve</surname><given-names>A</given-names></name>
<name><surname>Arsenault</surname><given-names>V</given-names></name>
<name><surname>Lacroix</surname><given-names>J</given-names></name>
<name><surname>Tucci</surname><given-names>M</given-names></name>
</person-group><article-title>Neonatal red blood cell transfusion</article-title><source>Vox Sang</source><year>2021</year><volume>116</volume><issue>4</issue><fpage>366</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/vox.13036</pub-id><pub-id pub-id-type="pmid">33245826</pub-id>
</element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stutchfield</surname><given-names>CJ</given-names></name>
<name><surname>Jain</surname><given-names>A</given-names></name>
<name><surname>Odd</surname><given-names>D</given-names></name>
<name><surname>Williams</surname><given-names>C</given-names></name>
<name><surname>Markham</surname><given-names>R</given-names></name>
</person-group><article-title>Foetal haemoglobin, blood transfusion, and retinopathy of prematurity in very preterm infants: a pilot prospective cohort study</article-title><source>Eye (Lond)</source><year>2017</year><volume>31</volume><issue>10</issue><fpage>1451</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/eye.2017.76</pub-id><pub-id pub-id-type="pmid">28548651</pub-id>
</element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boskabadi</surname><given-names>H</given-names></name>
<name><surname>Shoeibi</surname><given-names>N</given-names></name>
<name><surname>Bagheri</surname><given-names>F</given-names></name>
<name><surname>Pourbadakhshan</surname><given-names>N</given-names></name>
<name><surname>Moradi</surname><given-names>A</given-names></name>
<name><surname>Zakerihamidi</surname><given-names>M</given-names></name>
</person-group><article-title>Potential role of bilirubin in preventing retinopathy of prematurity</article-title><source>Curr Pediatr Rev</source><year>2023</year><volume>19</volume><issue>2</issue><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.2174/1573396318666220819151154</pub-id><pub-id pub-id-type="pmid">35986544</pub-id>
</element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaton</surname><given-names>DD</given-names></name>
<name><surname>Gold</surname><given-names>J</given-names></name>
<name><surname>Axer-Siegel</surname><given-names>R</given-names></name>
<name><surname>Wielunsky</surname><given-names>E</given-names></name>
<name><surname>Naor</surname><given-names>N</given-names></name>
<name><surname>Nissenkorn</surname><given-names>I</given-names></name>
</person-group><article-title>Evaluation of bilirubin as possible protective factor in the prevention of retinopathy of prematurity</article-title><source>Br J Ophthalmol</source><year>1991</year><volume>75</volume><issue>9</issue><fpage>532</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1136/bjo.75.9.532</pub-id><pub-id pub-id-type="pmid">1911654</pub-id>
</element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsiropoulos</surname><given-names>GN</given-names></name>
<name><surname>Seliniotaki</surname><given-names>AK</given-names></name>
<name><surname>Haidich</surname><given-names>AB</given-names></name>
<name><surname>Ziakas</surname><given-names>N</given-names></name>
<name><surname>Mataftsi</surname><given-names>A</given-names></name>
</person-group><article-title>Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review</article-title><source>Int Ophthalmol</source><year>2023</year><volume>43</volume><issue>3</issue><fpage>1027</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s10792-022-02480-6</pub-id><pub-id pub-id-type="pmid">36214992</pub-id>
</element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Liao</surname><given-names>Y</given-names></name>
<name><surname>Zeng</surname><given-names>R</given-names></name>
<name><surname>Zeng</surname><given-names>P</given-names></name>
<name><surname>Lan</surname><given-names>Y</given-names></name>
</person-group><article-title>Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in type-1 and threshold retinopathy of prematurity (ROP)</article-title><source>BMC Ophthalmol</source><year>2018</year><volume>18</volume><issue>1</issue><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s12886-018-0685-6</pub-id><pub-id pub-id-type="pmid">29378530</pub-id>
</element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomioka</surname><given-names>M</given-names></name>
<name><surname>Murakami</surname><given-names>T</given-names></name>
<name><surname>Okamoto</surname><given-names>F</given-names></name>
<name><surname>Kinoshita</surname><given-names>T</given-names></name>
<name><surname>Shinomiya</surname><given-names>K</given-names></name>
<name><surname>Nishi</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>five-year visual outcome of treatment for retinopathy of prematurity in infants weighing&#x02005;&#x0003c;&#x02005;500 g at birth: a multicenter cohort study from J-CREST</article-title><source>RETINA</source><year>2024</year><volume>44</volume><issue>4</issue><fpage>652</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/iae.0000000000004016</pub-id><pub-id pub-id-type="pmid">38064668</pub-id>
</element-citation></ref></ref-list></back></article>